The brief methylprednisolone administration is crucial to mitigate cardiac dysfunction after myocardial infarction

Area of Science:

• Cardiology
• Pharmacology
• Biomedical Science

Background:

• Acute myocardial infarction (AMI) is a leading cause of heart failure and mortality.
• Glucocorticoid administration post-AMI has yielded conflicting results, potentially due to drug type and timing.
• Understanding optimal glucocorticoid use is crucial for improving post-infarction outcomes.

Purpose of the Study:

• To evaluate the impact of brief methylprednisolone acetate administration on cardiac adaptation following AMI.
• To determine if early methylprednisolone acetate treatment can mitigate adverse ventricular remodeling.
• To investigate the effects on cardiac function, hypertrophy, congestion, and molecular markers.

Main Methods:

• Male Wistar rats were subjected to sham operation (SHAM), AMI, or AMI treated with a single methylprednisolone acetate dose (AMI+M).
• Cardiac function was assessed after 56 days.
• Tissue analysis included hypertrophy, congestion, oxidative stress, and matrix metalloproteinase-2 (MMP-2) activity.

Main Results:

• Methylprednisolone acetate treatment significantly attenuated MMP-2 activity.
• The AMI+M group exhibited reduced cardiac dilatation and prevented pulmonary congestion.
• Cardiac hypertrophy was also avoided in the methylprednisolone acetate-treated group.

Conclusions:

• A single, early dose of methylprednisolone acetate post-AMI demonstrates therapeutic potential.
• This treatment effectively attenuates detrimental ventricular remodeling processes.
• Methylprednisolone acetate may represent a viable therapeutic strategy for managing post-infarction cardiac dysfunction.